Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX) (Paris:ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response
PARIS (BUSINESS WIRE) Regulatory News:Onxeo S.A. (Euronext Growth Paris: ALONX) (Paris:ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced new date for the publication of its 2022 full-yea.
The annual general meeting will be held on June 6, 2023PARIS (BUSINESS WIRE) Regulatory News:Onxeo S.A. (Euronext Growth Paris: ALONX) (Paris:ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today anno.
The annual general meeting will be held on June 6, 2023 Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX) (Paris:ALONX), a clinical-stage biotechnology company specializing in the development
PARIS (BUSINESS WIRE) Regulatory News:Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced that the Extraordinary General Meet.